Log in to save to my catalogue

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cance...

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cance...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2406949682

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

About this item

Full title

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Publisher

New York: Nature Publishing Group US

Journal title

Nature medicine, 2020-06, Vol.26 (6), p.878-885

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Programmed cell death 1 (PD-1) inhibitors have limited effect in pancreatic ductal adenocarcinoma (PDAC), underscoring the need to co-target alternative pathways. CXC chemokine receptor 4 (CXCR4) blockade promotes T cell tumor infiltration and is synergistic with anti-PD-1 therapy in PDAC mouse models. We conducted a phase IIa, open-label, two-coho...

Alternative Titles

Full title

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2406949682

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2406949682

Other Identifiers

ISSN

1078-8956,1546-170X

E-ISSN

1546-170X

DOI

10.1038/s41591-020-0880-x

How to access this item